<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17930" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Astrocytoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kapoor</surname>
            <given-names>Mayank</given-names>
          </name>
          <aff>All India Institute of Medical Sciences (AIIMS) Rishikesh</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayank Kapoor declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17930.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Astrocytoma arises from astrocytes, the star-shaped glial cells found in the cerebrum. Constituting 60% of brain tumors, glial tumors include astrocytoma as the most prevalent form of glioma. While primarily impacting the brain, they can also affect the spinal cord. These tumors pose a significant threat to individuals across various age groups, contributing to both mortality and morbidity. Early diagnosis and prompt treatment are crucial in mitigating the serious consequences associated with astrocytomas.</p>
        <p>This educational course provides&#x000a0;a comprehensive understanding of astrocytomas, exploring their origin, pathology, classification, and clinical management. It reviews the latest advancements in diagnosis, treatment modalities, and emerging therapies for this prevalent form of glioma. Participants will gain insight into astrocytoma management, enhancing clinical knowledge and improving patient care outcomes. The activity also highlights the role of the interprofessional team in optimizing care coordination for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical signs and symptoms of progressive collapsing foot deformity, including medial arch collapse, hindfoot valgus, and forefoot abduction.</p></list-item><list-item><p>Differentiate progressive collapsing foot deformity from other foot pathologies such as plantar fasciitis, Achilles tendonitis, and Charcot arthropathy based on physical examination findings and diagnostic imaging.</p></list-item><list-item><p>Implement appropriate non-surgical interventions for early-stage progressive collapsing foot deformity, including orthotic devices, physical therapy, and activity modification.</p></list-item><list-item><p>Assess&#x000a0;interprofessional team strategies for improving comprehensive care and communication for astrocytoma patients.&#x000a0;</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17930&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17930">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17930.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Astrocytomas represent a significant and complex subset of brain tumors originating from astrocytes, the star-shaped glial cells that play a critical role in supporting neuronal function within the cerebrum. Amongst brain tumors, glial tumors comprise 60% of the tumors. As the most common form of glioma, astrocytomas primarily affect the brain, although they can also involve the spinal cord. These tumors present a considerable clinical challenge due to their prevalence and the serious morbidity and mortality they cause across all age groups. The etiology of astrocytomas remains largely elusive, with ionizing radiation being the only well-established risk factor. Associations with other potential risk factors, such as electromagnetic fields, head injury, or occupational exposures, are not yet supported by conclusive evidence.</p>
      </sec>
      <sec id="article-17930.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>No underlying cause has been identified for the majority of primary brain tumors, and the only established risk factor is exposure to ionizing radiation.<xref ref-type="bibr" rid="article-17930.r1">[1]</xref>&#x000a0;Children who receive prophylactic radiation for acute lymphocytic leukemia may have a 22 times higher&#x000a0;risk of developing a central nervous system (CNS) malignancy within about 5 to 10 years.&#x000a0;It has been shown that pituitary adenoma radiation therapy carries 16 times more risk of glioma development.<xref ref-type="bibr" rid="article-17930.r2">[2]</xref>&#x000a0;An association with other factors like exposure to electromagnetic fields (cellular telephones), head injury, or occupational risk factors is unproven.<xref ref-type="bibr" rid="article-17930.r3">[3]</xref></p>
        <p>A minority of patients have a family history of brain tumors. There is a genetic susceptibility to glioma development, for example, in diseases like Turcot syndrome,&#x000a0;<italic toggle="yes">p53</italic>&#x000a0;mutations (Li-Fraumeni syndrome), and neurofibromatosis type 1 (NF1). Amongst low-grade astrocytomas, about 66% demonstrate <italic toggle="yes">p5</italic>3 mutations.<xref ref-type="bibr" rid="article-17930.r4">[4]</xref></p>
      </sec>
      <sec id="article-17930.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Understanding epidemiological patterns for astrocytoma is&#x000a0;important for identifying risk factors and improving early detection&#x000a0;across&#x000a0;various populations and age groups.</p>
        <p>
<bold>Race</bold>
</p>
        <p>Minimal racial differences have been found.<xref ref-type="bibr" rid="article-17930.r5">[5]</xref></p>
        <p>
<bold>Gender</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>There appears to be no&#x000a0;gender dominance in pilocytic astrocytomas.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1.</p>
          </list-item>
        </list>
        <p>
<bold>Age</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The likelihood of&#x000a0;pilocytic astrocytoma increases&#x000a0;during&#x000a0;the first&#x000a0;2 decades of life. Low-grade astrocytomas are predominant in individuals aged 30 to 40, comprising&#x000a0;about one-fourth of adult cases.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>The age distribution of patients with low-grade astrocytomas is as follows:
<list list-type="bullet"><list-item><p>10%: younger than 20&#x000a0;</p></list-item><list-item><p>60%: 20 to 45 years&#x000a0;</p></list-item><list-item><p>30%: older than 45 years&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>For grade&#x000a0;3 astrocytoma, the mean age at diagnosis is&#x000a0;approximately 40 years.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17930.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of astrocytoma involves the abnormal proliferation of astrocytes, glial cells that provide structural and metabolic support to neurons in the CNS. Multiple mechanisms result in the local effects of astrocytoma. These include direct invasion and competition for oxygen, leading to hypoxic injury to normal brain parenchyma. The tumor microenvironment, which includes interactions with other cell types, extracellular matrix components, and blood vessels, also influences tumor progression. Free radicals, neurotransmitters, and inflammatory mediators also disturb homeostasis. This complex interplay contributes to the heterogeneity and resistance to therapy often observed in astrocytoma cases. Understanding the molecular and cellular mechanisms underlying astrocytoma development is essential for advancing diagnostic and therapeutic approaches.</p>
        <p>Genetic mutations and alterations in signaling pathways, such as the PI3K/AKT/mTOR and MAPK pathways, are often implicated in the uncontrolled growth and survival of these cells. These mutations can lead to the disruption of normal cellular processes, including cell cycle regulation, apoptosis, and differentiation. As a result, astrocytomas can vary in their aggressiveness, from relatively slow-growing pilocytic astrocytomas to highly malignant glioblastomas. The mass effect of the tumor produces various clinical signs and symptoms.</p>
      </sec>
      <sec id="article-17930.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Historically, gliomas were classified by morphological features based&#x000a0;on their resemblance to normal tissue.&#x000a0;Tumors resembling astrocytes are termed astrocytomas, and tumors similar to oligodendrocytes are referred to as oligodendrogliomas. Recent advances in molecular profiling have revolutionized the diagnostic and classification approach, leading to an integrated morphological and molecular classification that offers greater clinical relevance. These advances were introduced in the revised fourth edition of the World Health Organization (WHO) Classification of Central Nervous System Tumors in 2016 and further refined in the fifth edition (WHO 2021), which fully integrates molecular diagnostics with histological features. Immunohistochemistry identifies <italic toggle="yes">IDH, ATRX, p53,</italic> and other important mutations.&#x000a0;This&#x000a0;new classification is also the first to classify pediatric gliomas separately.</p>
        <p>WHO classification (2016) classified diffuse astrocytomas as grades 2, 3, and 4. Grade&#x000a0;1 infiltrating astrocytoma&#x000a0;was not mentioned. The classification&#x000a0;was based on 4&#x000a0;characteristics as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nuclear atypia: nuclear pleomorphism and hyperchromasia&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mitoses:
<list list-type="bullet"><list-item><p>Has to be unequivocal</p></list-item><list-item><p>Ki67 proliferation index is used to separate grade&#x000a0;2 tumors from grade 3.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Microvascular proliferation
<list list-type="bullet"><list-item><p>Glomeruloid type is the most common, prognostically of lesser significance as it is found in lower-grade gliomas (such as pilocytic astrocytoma)</p></list-item><list-item><p>Endothelial proliferation is present in the large vessel lumen. It is less common and has more of an association with high-grade gliomas.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Necrosis:&#x000a0;
<list list-type="bullet"><list-item><p>Coagulative necrosis</p></list-item><list-item><p>Pseudopalisading necrosis</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>WHO Histological Grading: Diffuse Astrocytomas</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Grade&#x000a0;2 (diffuse astrocytoma): nuclear atypia alone&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Grade&#x000a0;3 (anaplastic astrocytoma): nuclear atypia&#x000a0;and focal/dispersed anaplasia. Prominent proliferation activity and mitoses are present.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Grade&#x000a0;4 (glioblastoma): nuclear atypia, mitoses, microvascular proliferation, or necrosis</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>WHO Histological Grading: Localized Astrocytomas</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Pilocytic astrocytoma: corresponds to WHO grade 1 (see <bold>Image.</bold>&#x000a0;Microscopic Features of Pilocytic Astrocytoma)
<list list-type="bullet"><list-item><p>Does not recommend definitive grade allotment yet for pilomyxoid astrocytoma&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Subependymal giant cell astrocytoma: grade 1&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pleomorphic xanthoastrocytoma: grade 2&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Anaplastic pleomorphic astrocytoma: grade 3&#x000a0;<xref ref-type="bibr" rid="article-17930.r6">[6]</xref><xref ref-type="bibr" rid="article-17930.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official WHO (cIMPACT-NOW) facilitated the WHO classification modifications. The recent 2021 WHO classification utilizes advanced molecular diagnostics to classify CNS tumors. Clinical and molecular differences among diffuse gliomas occurring in adults (adult type) and children (pediatric type) are recognized.<xref ref-type="bibr" rid="article-17930.r8">[8]</xref></p>
        <p>Adult-type glioma classification is now divided into only 3 distinct groups:</p>
        <list list-type="bullet">
          <list-item>
            <p>Astrocytoma <italic toggle="yes">IDH</italic>-mutant: Grades 2, 3, and&#x000a0;4 &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Oligodendroglioma <italic toggle="yes">IDH</italic>-mutant and 1p/19q-codeleted: Grades 2 and&#x000a0;3 &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Glioblastoma, <italic toggle="yes">IDH</italic>-wildtype: Grade 4, including molecular diagnosis of <italic toggle="yes">TERT</italic> promoter mutation,&#x000a0; &#x000a0;<italic toggle="yes">epidermal growth factor receptor</italic>&#x000a0;(<italic toggle="yes">EGFR)</italic> gene amplification, and gain of chromosome 7 and loss of chromosome 10. As per the revision classification, <italic toggle="yes">IDH</italic>-wildtype astrocytoma grades&#x000a0;2 and&#x000a0;3 are no longer recognized.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Astrocytoma Tumor Grades</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Grade&#x000a0;1&#x000a0;</bold>
<list list-type="bullet"><list-item><p>Low-grade tumors</p></list-item><list-item><p>Includes&#x000a0;pilocytic astrocytoma and subependymal giant cell astrocytoma</p></list-item><list-item><p>usually occur in children and young adults</p></list-item><list-item><p>not considered malignant as it does not spread in the brain&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Grade&#x000a0;2 (previously diffuse)&#x000a0;</bold>
<list list-type="bullet"><list-item><p>Usually seen in adults</p></list-item><list-item><p>May progress to glioblastoma</p></list-item><list-item><p>Without microvascular proliferation or necrosis</p></list-item><list-item><p>Cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) non-deleted&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Grade&#x000a0;3 (previously anaplastic)&#x000a0;</bold>
<list list-type="bullet"><list-item><p>Also usually seen in adults</p></list-item><list-item><p>Characterized by a lack of endothelial proliferation&#x000a0;and necrosis</p></list-item><list-item><p>CDKN2A/B non-deleted&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Grade&#x000a0;4 (previously glioblastoma)</bold>
<list list-type="bullet"><list-item><p>The most common malignant brain tumor</p></list-item><list-item><p>Peak age is approximately 65 years</p></list-item><list-item><p>Bad prognostication</p></list-item><list-item><p>Variants: giant cell glioblastoma and gliosarcoma</p></list-item><list-item><p>With microvascular proliferation or necrosis</p></list-item><list-item><p>CDKN2A/B deleted</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Specific Tumor Types</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Diffuse astrocytoma, MYB or MYBL1-altered</bold>
<list list-type="bullet"><list-item><p>Now, WHO grade 1</p></list-item><list-item><p><italic toggle="yes">IDH</italic>-wildtype pediatric-type diffuse low-grade glioma</p></list-item><list-item><p>Benign clinical course</p></list-item><list-item><p>Low recurrence after resection alone&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Pleomorphic xanthoastrocytoma&#x000a0;</bold>
<list list-type="bullet"><list-item><p>Prognosis is typically good</p></list-item><list-item><p>Children and young adults affected</p></list-item><list-item><p>Big lipidized cells</p></list-item><list-item><p>May mimic malignant tumor&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Subependymal giant cell astrocytoma&#x000a0;</bold>
<list list-type="bullet"><list-item><p>Located mostly intraventricularly</p></list-item><list-item><p>Benign in nature</p></list-item><list-item><p>Affects the adolescent age group</p></list-item><list-item><p>Associated with tuberous sclerosis&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>H3 K27M mutant diffuse midline glioma</bold>
<list list-type="bullet"><list-item><p>High-grade</p></list-item><list-item><p>Midline location, including the spinal cord, brainstem, or thalamus</p></list-item><list-item><p>Adolescents&#x000a0;and children mainly&#x000a0;affected</p></list-item><list-item><p>Diffuse pontine intrinsic glioma included</p></list-item><list-item><p>New entry after the 2016 WHO classification</p></list-item><list-item><p>Poor prognosis usually presents as follows:
<list list-type="bullet"><list-item><p>With the absence of <italic toggle="yes">EGFR</italic> amplification&#x000a0;</p></list-item><list-item><p>With the presence of unmethylated O<sup>6</sup>-methylgaunine-DNA-methyltransferase (<italic toggle="yes">MGMT</italic>) promoter</p></list-item></list>
</p></list-item><list-item><p>Enhancement&#x000a0;on MRI: may or may not be present</p></list-item><list-item><p>Histologically may range from&#x000a0;minimum hypercellularity to full-blown glioblastoma&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Gliomatosis cerebri</bold>
<list list-type="bullet"><list-item><p>The old term used for extensive&#x000a0;and diffuse astrocytomas</p></list-item><list-item><p>Not a distinct entity since 2016</p></list-item><list-item><p>Radiological evidence of &#x0003e;3 lobe involvement required bilaterally</p></list-item><list-item><p>Now, WHO grade&#x000a0;3</p></list-item><list-item><p>The division into 2 types is possible based on&#x000a0;solid component presence as follows:
<list list-type="bullet"><list-item><p>Type 1: No <italic toggle="yes">IDH 1/2</italic> mutation, diffusely growing</p></list-item><list-item><p>Type 2: <italic toggle="yes">IDH 1</italic> mutation positive, a solid component present</p></list-item></list>
</p></list-item><list-item><p>Genetically overlaps with diffuse astrocytic gliomas, glioblastoma, and oligodendrogliomas&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Gliosarcoma</bold>&#x000a0;
<list list-type="bullet"><list-item><p>WHO considers&#x000a0;this a variant of&#x000a0;glioblastoma</p></list-item><list-item><p>Quite rare, with only about 200 case reports</p></list-item><list-item><p>Demonstrates glioblastoma and sarcoma components (fibroblastic, osseous, cartilage, smooth and striated muscle, fat cells)</p></list-item><list-item><p>Similar to glioblastomas, usually found in the temporal lobe</p></list-item><list-item><p>Prognositicallly like glioblastoma</p></list-item><list-item><p>Immunohistochemistry includes the following:
<list list-type="bullet"><list-item><p>The astrocytic component is glial fibrillary acidic protein (GFAP) positive&#x000a0;and&#x000a0;spindle cell negative</p></list-item><list-item><p>Smooth muscle part (gliomyosarcoma) is smooth muscle antibody (SMA)&#x000a0;and factor VIII positive&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Gliofibroma</bold>
<list list-type="bullet"><list-item><p>Very rare</p></list-item><list-item><p>Usually found in children</p></list-item><list-item><p>Has a fibroblastic component, which is nonmalignant</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17930.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>A thorough history of patients with astrocytoma is a critical component of the diagnostic process, providing valuable insights into symptoms' onset, progression, and nature. Symptoms can be divided into&#x000a0;2 categories: general&#x000a0;and focal. General symptoms include headache (usually early morning), nausea, vomiting, cognitive difficulties, personality changes, and gait disorders. Localizing symptoms include seizures, aphasia, or visual field defects. About 50%&#x000a0;of patients with supratentorial brain tumors may present with seizures. A visual field defect is often unnoticed by the patient and may be revealed after it leads to injury, such as&#x000a0;motor vehicle accidents.&#x000a0;</p>
        <p>It is essential to document the duration, frequency, and severity of these symptoms and any factors that exacerbate or alleviate them. Additionally, the patient's medical history, including prior head injuries, exposure to ionizing radiation, and family history of neurological disorders or cancers, should be thoroughly explored. Clinicians should also assess the patient's functional status, noting any impact on daily activities and quality of life. This comprehensive history helps to establish a timeline of symptom development, identify potential risk factors, and guide further diagnostic evaluations, ultimately contributing to a more accurate and timely diagnosis of astrocytoma.</p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>The physical examination of patients with astrocytoma involves a comprehensive neurological assessment to evaluate the extent and impact of the tumor on the CNS. During the neurological examination, attention is given to cranial nerve function, motor strength, coordination, sensory perception, and reflexes. Specific tests may include evaluating visual fields, assessing gait and balance, and testing for signs of increased intracranial pressure, such as papilledema. These findings help localize the tumor and gauge its severity, guiding further diagnostic imaging and treatment planning. The examination results, imaging studies, and histological analysis are crucial for establishing an accurate diagnosis and developing an effective treatment strategy.</p>
      </sec>
      <sec id="article-17930.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation of astrocytomas involves a thorough clinical assessment, advanced imaging techniques, and histopathological analysis.&#x000a0;A definitive diagnosis is obtained through a biopsy, where histopathological examination and molecular profiling&#x000a0;are performed. These evaluations are critical for accurately grading the tumor, guiding treatment decisions, and predicting prognosis.</p>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>Magnetic resonance imaging (MRI) is the best imaging modality for diagnosing astrocytoma. Gadolinium contrast-enhanced magnetic resonance (MR) imaging should be used whenever possible. If there is any contraindication for MRI, such as joint implants or pacemakers in situ, computed tomography (CT) may be performed. Lower-grade gliomas are contrast-enhancing, so fluid-attenuated inversion recovery sequences of MRI are done.</p>
        <p>If a tumor is found, a neurosurgeon must perform a biopsy on it. This involves the removal of a small amount of tumor tissue, which is then sent to a neuropathologist for examination and grading. CT appearance of low-grade astrocytomas is also generally not very definitive. The tuors&#x000a0;are homogeneous, not well defined, and appear as poorly defined and non-contrast enhancing lesions. In anaplastic astrocytomas, there may be some contrast enhancement. There may be a possible metastatic disease; hence, whole-body imaging should also be considered to look for an alternate primary.</p>
        <p>On MRI, T2 hyperintensity is seen in astrocytomas, whereas on T1, there is isointensity. Tumor vascularity is significant; new techniques are being developed to identify it. These include arterial spin labeling and dynamic contrast enhancement MRI. Functional MRI is an upcoming imaging modality; this is useful pre-surgery to demarcate various areas of the brain based on functionality. Other modalities include positron emission tomography (PET) scan, magnetic resonance spectroscopy, and perfusion imaging. These modalities may provide information about the metabolic action in the tumor, the blood flow characteristics, and the constitution of the tumor.&#x000a0;With this approach, it can be determined whether the lesion is progressive or necrosed after chemotherapy and radiotherapy.&#x000a0;</p>
      </sec>
      <sec id="article-17930.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Glioma Treatment Recommendations Based on Tumor Grade</bold>
</p>
        <p>
<bold>Grade 2</bold>
<italic toggle="yes">&#x000a0;</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Surgery is recommended with maximal safe resection.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Unfavorable prognostic factors: age&#x000a0;older than&#x000a0;40, dimension &#x02265;4 cm, tumor crossing midline, and presence of neurologic deficit before resection; &#x02265;3 high-risk factors.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Low-risk, patients younger than 40 can be observed.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>High-risk patients: fractionated external-beam radiotherapy (EBRT) plus adjuvant chemotherapy is recommended.<xref ref-type="bibr" rid="article-17930.r9">[9]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>The standard radiation dose for low-grade astrocytomas is 45 Gy to 54 Gy, delivered in 1.8 Gy to 2.0 Gy fractions.&#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Clinical target volume (CTV) is a 1 cm expansion around the gross tumor volume (GTV).&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Adjuvant therapy includes&#x000a0;temozolomide&#x000a0;150&#x000a0;to 200 mg/m<sup>2</sup>/day orally on days 1 to 5 of a 28-day cycle (12 cycles) or PCV (procarbazine, lomustine, vincristine) for 6 cycles.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Recurrences or progressive, low-grade disease (previously untreated): Temozolomide 75 mg/m<sup>2</sup> by mouth daily on days 1 to 21 or 150&#x000a0;to 200 mg/m<sup>2</sup>&#x000a0;by mouth on days 1&#x000a0;to 5 of a 28-d cycle until disease progression or for a maximum of 24 cycles.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Postoperative radiation therapy is often employed for unresectable, residual, or recurrent tumors.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chemotherapy is often used for low-grade oligodendrogliomas, particularly tumors with the 1p19q deletion, which is a marker for tumor susceptibility to chemotherapy.</p>
          </list-item>
        </list>
        <p>
<bold>Grade&#x000a0;3</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Standard of care: surgical resection followed by EBRT (54 Gy to 59.4 Gy in 1.8 Gy fractions) is recommended.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Postradiation therapy: continue temozolomide at a dose of 150&#x000a0;to 200 mg/m<sup>2</sup>/day by mouth on days 1 to 5 every 28 days for 12 cycles&#x000a0;<bold>OR</bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Procarbazine,&#x000a0;lomustine,&#x000a0;vincristine (PCV)): lomustine (CCNU) 90&#x000a0;to 130 mg/m<sup>2</sup>&#x000a0;by mouth on day 1 (max-200 mg)&#x000a0;<bold>plus&#x000a0;</bold>procarbazine 60 to 75 mg/m2&#x000a0;PO on days 8 to 21&#x000a0;<bold>plus&#x000a0;</bold>vincristine 1.4 mg/m<sup>2</sup> IV (not to exceed 2 mg/dose) on days 8 and 29; administer every 6 weeks for up to 6 cycles.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Grade&#x000a0;4</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Standard of care is surgical resection followed by EBRT (59.4 Gy to 60 Gy in 1.8 Gy fractions) and temozolomide 75 mg/m<sup>2</sup>/day orally on days 1 to 42, usually 1 to 1.5 hours before radiation, followed by adjuvant temozolomide 6 cycles&#x000a0;<xref ref-type="bibr" rid="article-17930.r7">[7]</xref><xref ref-type="bibr" rid="article-17930.r10">[10]</xref>&#x000a0;<bold>OR&#x000a0;</bold></p>
          </list-item>
          <list-item>
            <p>Postradiation therapy: adjuvant&#x000a0;temozolomide at higher doses of 150 to 200 mg/m<sup>2</sup>/day orally on days 1 to 5 every 28 days&#x000a0;for 12 cycles is recommended.<xref ref-type="bibr" rid="article-17930.r11">[11]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hematologic toxicity may be higher with concurrent treatment, with a higher incidence&#x000a0;in women.</p>
          </list-item>
        </list>
        <p>The phenomena of pseudoprogression after radiation therapy may be seen; this is the development of progressive enhancing lesions on MRI, representing radiation necrosis rather than active tumors.</p>
        <p><bold>Recommendations for recurrent tumors</bold>&#x000a0;include reoperation, carmustine wafers, alternate chemotherapeutic regimens, and investigational&#x000a0;<italic toggle="yes">IDH</italic>-targeted approaches.&#x000a0;Re-radiation is rarely helpful; an additional 36 Gy in 18 fractions may be given. Bevacizumab, a humanized VEGF monoclonal antibody, has activity in recurrent glioblastoma, potentially increasing progression-free survival (PFS) and reducing peritumoral edema and glucocorticoid use.<xref ref-type="bibr" rid="article-17930.r12">[12]</xref>&#x000a0;<italic toggle="yes">IDH</italic>-targeted approaches, including vorasidenib and other small-molecule inhibitors of mutant&#x000a0;<italic toggle="yes">IDH1</italic>&#x000a0;and&#x000a0;<italic toggle="yes">2</italic>&#x000a0;(ivosidenib, olutasidenib, safusedinib), are in trials. Vaccine strategies are also being explored.&#x000a0;Recurrent glioblastoma treatment decisions must take into consideration factors such as previous therapy, time to relapse, performance status, and quality of life. Whenever possible, patients with recurrent disease should be enrolled in clinical trials.&#x000a0;</p>
        <p>
<bold>Treatment Approaches</bold>
</p>
        <p>As with&#x000a0;other malignancies, a multimodal treatment approach is undertaken, including surgical, medical, and radiation oncology.&#x000a0;Low-grade astrocytomas: No clear superiority of any particular modality is known. As these low-grade tumors can be pretty indolent, questions arise about the risk-benefit ratio of undertaking any intervention. A study by Ishkanian et al demonstrated the efficacy of adjuvant radiotherapy for pilocytic astrocytoma (WHO grade 1); it prolongs PFS at 5 years and 10 years compared to observation.<xref ref-type="bibr" rid="article-17930.r13">[13]</xref>&#x000a0;Overall, survival was equal.</p>
        <p>Grade 2 astrocytoma: radiotherapy and adjuvant chemotherapy are better than radiotherapy alone. Results from a trial showed that chemotherapy with vincristine, procarbazine, and lomustine following radiotherapy leads to better 10-year PFS (51%&#x000a0;vs 21%).<xref ref-type="bibr" rid="article-17930.r14">[14]</xref>&#x000a0;Grade 3 astrocytomas: Multimodal therapy includes&#x000a0;surgery, radiation, and chemotherapy (adjuvant temozolomide). Data regarding concurrent temozolomide is lacking, although some studies showed improved survival (46% vs 29%).&#x000a0;<italic toggle="yes">IDH</italic>&#x000a0;mutation is also associated with improved 5-year survival (79% vs 22%).<xref ref-type="bibr" rid="article-17930.r15">[15]</xref>&#x000a0;Response to chemotherapy is better in anaplastic astrocytomas than glioblastomas. In the event of recurrence, temozolomide shows a better response. Nitrosourea-treated recurrent tumors showed about 35% response with temozolomide. Moreover, 6-month survival rates were also better (46% vs 31%).<xref ref-type="bibr" rid="article-17930.r6">[6]</xref>&#x000a0;Adjuvant carmustine shows a slight survival benefit.</p>
        <p>
<bold>Other Medications&#x000a0;</bold>
</p>
        <p>Prophylactically starting antiepileptics is controversial. Those who have a complaint of seizure should be started on antiepileptics. For seizures, the patient is usually started on levetiracetam, topiramate, lamotrigine, valproic acid, and lacosamide. These drugs interfere less with the hepatic microsomal enzyme system. Other drugs, such as phenytoin and carbamazepine, are used less frequently as they are potent enzyme inducers that can interfere with glucocorticoid metabolism and chemotherapeutic agents' metabolism.</p>
        <p>Corticosteroids are also used because their anti-inflammatory action provides excellent symptomatic relief and decreases the mass effect. Dexamethasone is the glucocorticoid of choice because of its low mineralocorticoid activity. Initial doses are typically 12 to 16 mg/d in divided doses orally or intravenously (both are equivalent). Concurrent prophylaxis for gastrointestinal ulcers should be prescribed with corticosteroid administration.</p>
        <p>Venous thromboembolic disease occurs in 20% to 30% of patients with high-grade gliomas and brain metastasis; hence, prophylactic anticoagulants should be used during hospitalization and in nonambulatory patients. Those who have had deep venous thrombosis or pulmonary embolus can safely receive therapeutic doses of anticoagulation without increasing the risk of hemorrhage into the tumor.</p>
      </sec>
      <sec id="article-17930.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Before confirming a diagnosis of astrocytoma, it's crucial to consider other potential conditions that may present with similar symptoms or imaging findings. The differential diagnosis for astrocytoma includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Glioblastoma multiforme</p>
          </list-item>
          <list-item>
            <p>Brain metastasis</p>
          </list-item>
          <list-item>
            <p>Brain abscess</p>
          </list-item>
          <list-item>
            <p>Oligodendroglioma</p>
          </list-item>
          <list-item>
            <p>Encephalitis</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Primary central nervous lymphoma</p>
          </list-item>
          <list-item>
            <p>Toxoplasmosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17930.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Maximum safe resection is the preferred surgical approach. Surgery aims&#x000a0;to remove&#x000a0;or debulk the tumor. Histological diagnosis is made possible by the tissue biopsy provided by the surgeon. Other symptom-relieving procedures include intracranial tension-reducing procedures like ventriculoperitoneal (VP) shunting and external ventricular drain insertion.&#x000a0;Complete resection (&#x0003e;98% based on volumetric MRI) improves median survival compared with subtotal resection (13 months vs 8.8 months).<xref ref-type="bibr" rid="article-17930.r16">[16]</xref>&#x000a0;For low-grade gliomas, supratotal resection is also advocated (ie, removing tissue beyond the MRI-defined abnormalities), suggesting an increase in overall survival with this strategy.<xref ref-type="bibr" rid="article-17930.r17">[17]</xref>&#x000a0;</p>
        <p>The urgency of neurosurgical evaluation depends on whether the patient is clinically stable, the symptoms' severity, and the tumor's size and location. Preoperative evaluation includes MRI and diffusion tensor imaging.</p>
        <p>
<bold>Intraoperative techniques</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In a multicenter trial including 314 patients who underwent resection of a newly diagnosed glioblastoma, the complete resection rate was similar for intraoperative magnetic resonance imaging (iMRI) or 5-aminolevulinic acid (81% and 78%, respectively).<xref ref-type="bibr" rid="article-17930.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>In a trial of iMRI versus conventional neuronavigation, iMRI use led to better PFS.<xref ref-type="bibr" rid="article-17930.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Timing of surgery</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Large tumors with significant symptoms: immediate&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Small tumors with minimal symptoms: immediate (preferred) or delayed&#x000a0;<xref ref-type="bibr" rid="article-17930.r20">[20]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17930.s12" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>
<bold>Antineoplastic Agents</bold>
</p>
        <p>Temozolomide is an oral alkylating agent converted to 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) at physiologic pH. This agent is 100% bioavailable, and approximately 35% crosses the blood-brain barrier. Based on the CATNON trial, adjuvant treatment consists of 12 monthly cycles, beginning 1 month after radiotherapy completion. The first cycle dose is 150 mg/m<sup>2</sup>, followed by 200 mg/m<sup>2</sup> orally for 5 days in a 28-day&#x000a0;cycle.&#x000a0;Temozolomide is moderately emetogenic; hence, antiemetic prophylaxis is required with 5-HT3 antagonists. The Procarbazine, Lomustine, and Vincristine (PCV) regimen involves a 6- to 8-week cycle length for 6 cycles. Eight-week cycles may be preferred for grade 2 tumors.<xref ref-type="bibr" rid="article-17930.r21">[21]</xref>&#x000a0;mTOR inhibitors are also proposed for the treatment of grade 1 astrocytomas.</p>
      </sec>
      <sec id="article-17930.s13" sec-type="Staging">
        <title>Staging</title>
        <p>Staging is not&#x000a0;performed&#x000a0;in patients with astrocytoma. Grading only is determined, as described previously, which is a determinant of prognosis.</p>
      </sec>
      <sec id="article-17930.s14" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Understanding the prognosis of astrocytomas is essential for guiding treatment decisions and providing realistic expectations to affected patients and their families.</p>
        <p>Typical survival ranges&#x000a0;are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>WHO grade&#x000a0;2 astrocytomas - less than 5 years</p>
          </list-item>
          <list-item>
            <p>WHO grade&#x000a0;3 astrocytomas - about 2 to 5 years</p>
          </list-item>
          <list-item>
            <p>WHO grade&#x000a0;4 astrocytomas - approximately 1 year</p>
          </list-item>
        </list>
        <p>Prognosis&#x000a0;is favorable for low-grade tumors, with survival times approaching 7 to 8 years post-surgery. In anaplastic astrocytoma, therapy focuses on improving symptoms. Radiotherapy of partially resected tumors increases postoperative survival rates. Survival rates after postsurgical radiation therapy are nearly double those of only surgical intervention (5 vs 2.2 years).</p>
        <p>Genetics also determines the prognosis of a particular tumor. Oligodendroglioma with Ch 1p19q changes responds better to PCV. Genetics is emerging as a pivotal field in the development of personalized tumor therapies.</p>
        <p>Kallikrein levels are associated with patient prognosis:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased kallikrein-related peptidases, KLK6 / KLK7-IR, leads to poor&#x000a0;outcomes</p>
          </list-item>
          <list-item>
            <p>Immunoreaction with KLK6/9&#x000a0; decreased survival&#x000a0;<xref ref-type="bibr" rid="article-17930.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17930.s15" sec-type="Complications">
        <title>Complications</title>
        <p>Managing astrocytoma cases can be fraught with numerous complications that can significantly impact outcomes and quality of life. Neurosurgical interventions, while often necessary for tumor resection, carry risks such as infection, bleeding, and neurological deficits due to damage to surrounding brain tissue. Postsurgical complications can include cerebral edema and seizures. Radiotherapy and chemotherapy, although critical for controlling tumor growth, can lead to&#x000a0;adverse&#x000a0;effects like fatigue, nausea, cognitive decline, and myelosuppression, increasing the risk of infections and anemia.</p>
        <p>Efficient drugs have been devised to manage these complications properly. Long-term complications may involve radiation necrosis, secondary malignancies, and progressive neurological deterioration. Additionally, the tumor's location and infiltrative nature can make complete resection challenging, leading to recurrence and requiring ongoing treatment. Managing these complications necessitates a comprehensive, multidisciplinary approach to balance effective tumor control with the mitigation of adverse effects, emphasizing the importance of supportive care and regular monitoring to address issues promptly.</p>
      </sec>
      <sec id="article-17930.s16" sec-type="Consultations">
        <title>Consultations</title>
        <p>Effectively managing astrocytomas cases involves consultations with various specialists to provide comprehensive care.&#x000a0;This collaborative approach may involve consultations with the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neuro-oncologists and neurosurgeons are essential for evaluating the tumor and planning surgical interventions.&#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Radiation oncologists and medical oncologists develop and administer appropriate radiotherapy and chemotherapy regimens.</p>
          </list-item>
          <list-item>
            <p>Neurologists are crucial for managing neurological symptoms and monitoring disease progression.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pathologists play a key role in diagnosing the specific tumor type and grade through histological and molecular analysis.</p>
          </list-item>
          <list-item>
            <p>Support from palliative care specialists is important for managing pain and improving quality of life, especially in advanced cases.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Rehabilitation specialists, including physical therapists, occupational therapists, and speech therapists, help address functional impairments and improve patient independence.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Psychologists or psychiatrists provide essential mental health support, addressing the emotional and cognitive impacts of the disease.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17930.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and patient education are pivotal in managing astrocytoma, focusing on both prevention and empowerment through knowledge. While specific causative factors for astrocytoma are largely unknown, minimizing exposure to known risk factors such as ionizing radiation is advisable. Patient education involves providing comprehensive information about the disease, its symptoms, and the importance of early detection and regular monitoring. Educating patients about the potential signs of astrocytoma, such as persistent headaches, seizures, and neurological changes, can lead to earlier diagnosis and treatment.</p>
        <p>Furthermore, empowering patients with knowledge about their treatment options, potential side effects, and strategies for managing symptoms can improve adherence to treatment plans and enhance quality of life. Effective patient education also includes discussions about lifestyle modifications, nutritional guidance, and psychosocial support, helping patients navigate their journey with astrocytoma more confidently and proactively.</p>
      </sec>
      <sec id="article-17930.s18" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Clinical pearls emphasize the importance of a holistic approach to treating astrocytomas, leveraging the latest advancements in diagnosis and treatment as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Recognize early symptoms such as persistent headaches, seizures, and focal neurological deficits for prompt evaluation.</p>
          </list-item>
          <list-item>
            <p>Effective management involves a team of neuro-oncologists, neurosurgeons, radiation oncologists, neurologists, pathologists, and rehabilitation specialists.</p>
          </list-item>
          <list-item>
            <p>Utilize molecular diagnostics, including&#x000a0;<italic toggle="yes">IDH</italic>&#x000a0;mutation status, to inform prognosis and guide treatment strategies.</p>
          </list-item>
          <list-item>
            <p>Aim for maximal safe resection to reduce tumor burden and improve outcomes while minimizing neurological deficits.</p>
          </list-item>
          <list-item>
            <p>Combine surgery, radiotherapy, and chemotherapy for optimal management tailored to the patient's specific tumor characteristics.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Address symptoms proactively with medications for seizures, pain management, and corticosteroids to reduce cerebral edema.</p>
          </list-item>
          <list-item>
            <p>Implement routine imaging follow-ups to detect tumor recurrence or progression early.</p>
          </list-item>
          <list-item>
            <p>Educate patients and families about the disease, treatment options, potential&#x000a0;adverse effects, and the importance of adherence to the treatment plan.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Provide access to psychosocial support and palliative care services to enhance quality of life, especially in advanced stages.</p>
          </list-item>
          <list-item>
            <p>Incorporate physical, occupational, and speech therapy to address functional impairments and improve patient independence.</p>
          </list-item>
          <list-item>
            <p>Consider enrolling eligible patients in clinical trials to access cutting-edge therapies and contribute to advancing treatment options.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Offer genetic counseling for patients with a family history of brain tumors to assess potential hereditary risks.</p>
          </list-item>
          <list-item>
            <p>Encourage healthy lifestyle choices, including proper nutrition and exercise, and avoid known risk factors like ionizing radiation exposure.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17930.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effectively managing astrocytoma cases requires an interprofessional approach involving physicians, advanced care practitioners, nurses, pharmacists, psychologists, and other health professionals. Each team member must bring specialized skills and strategies to enhance patient-centered care, improve outcomes, ensure patient safety, and boost team performance.&#x000a0;Early initiation of treatment after consultation with the oncology team comprising medical oncologists, surgical oncologists,&#x000a0;anesthetists, radiation oncologists, radiologists, and pathologists is a must.<xref ref-type="bibr" rid="article-17930.r23">[23]</xref></p>
        <p>Physicians and advanced care practitioners must utilize advanced diagnostic skills and keep abreast of the latest treatment protocols, integrating evidence-based practices into patient care. Surgeons need precise technical skills for tumor resection, while radiologists and oncologists should be adept at interpreting imaging studies and developing personalized radiation and chemotherapy plans. Nurses play a crucial role in monitoring patient status, managing symptoms, and providing emotional support. Pharmacists must ensure the safe and effective use of medications, addressing potential drug interactions and managing&#x000a0;adverse effects. Implementing safety protocols, such as surgical checklists, medication reconciliation, and infection control measures, is essential. Pharmacists and nurses should collaborate to ensure the safe administration of therapies.&#x000a0;</p>
        <p>Coordinating care across different specialties is crucial for managing patients with astrocytomas. Care coordinators or nurse navigators can play an essential role in ensuring that appointments, treatments, and follow-ups are well-organized. Effective care coordination helps prevent gaps in care, reduces redundancy, and ensures patients receive timely and comprehensive treatment.</p>
        <p>Clear and open communication among team members is vital. Regular case discussions facilitate the exchange of information and collaborative decision-making. Focusing on patient-centered care involves considering the patient's preferences, needs, and values. All team members should engage with patients and their families to understand their goals and concerns, providing education and support throughout the treatment journey. Shared decision-making empowers patients and fosters a collaborative approach to care.</p>
        <p>An interprofessional team is crucial in caring for patients with astrocytoma because it integrates diverse expertise from various healthcare disciplines, ensuring comprehensive and coordinated care that addresses all aspects of the patient's condition. Simulation exercises, quality improvement initiatives, and continuous professional development help teams stay cohesive and effective. Team performance can be enhanced through regular interdisciplinary meetings, effective communication strategies, and continuous professional development, fostering collaboration and improving patient outcomes.</p>
      </sec>
      <sec id="article-17930.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17930&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17930">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/astrocytoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17930">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17930/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17930">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17930.s21">
        <fig id="article-17930.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Microscopic Features of Pilocytic Astrocytoma. Hair-like cell processes can be observed with H&#x00026;E staining. Nephron, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/w/index.php?title=Special:MediaSearch&#x00026;search=Pilocytic+Astrocytoma&#x00026;type=image">Public Domain</ext-link>, via Wikimedia Commons&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screenshot__2020-06-15__at__14.06.44" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17930.s22">
        <title>References</title>
        <ref id="article-17930.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshikawa</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rabelo</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Telles</surname>
                <given-names>JPM</given-names>
              </name>
              <name>
                <surname>Figueiredo</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <article-title>Modifiable risk factors for glioblastoma: a systematic review and meta-analysis.</article-title>
            <source>Neurosurg Rev</source>
            <year>2023</year>
            <month>Jun</month>
            <day>20</day>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <pub-id pub-id-type="pmid">37340151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Br&#x000fc;stle</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ohgaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Ostertag</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kleihues</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene.</article-title>
            <source>Cancer</source>
            <year>1992</year>
            <month>May</month>
            <day>01</day>
            <volume>69</volume>
            <issue>9</issue>
            <fpage>2385</fpage>
            <page-range>2385-92</page-range>
            <pub-id pub-id-type="pmid">1314130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Perfetti</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Chokshi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Venugopal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ashford</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for glioblastoma are shared by other brain tumor types.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>2024</year>
            <season>Jan-Dec</season>
            <volume>43</volume>
            <fpage>9603271241241796</fpage>
            <pub-id pub-id-type="pmid">38520250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawengchao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Petmitr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ponglikitmongkol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chanyavanich</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sangruji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Theerapuncharoen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thangnipon</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.</article-title>
            <source>Anticancer Res</source>
            <year>2001</year>
            <season>Jul-Aug</season>
            <volume>21</volume>
            <issue>4A</issue>
            <fpage>2739</fpage>
            <page-range>2739-43</page-range>
            <pub-id pub-id-type="pmid">11724349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>PYM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DTM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations.</article-title>
            <source>Cancer Biol Med</source>
            <year>2022</year>
            <month>Nov</month>
            <day>01</day>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>1440</fpage>
            <page-range>1440-59</page-range>
            <pub-id pub-id-type="pmid">36350002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yung</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Prados</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Yaya-Tur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Brada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Albright</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bruner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dugan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zaknoen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.</article-title>
            <source>J Clin Oncol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>2762</fpage>
            <page-range>2762-71</page-range>
            <pub-id pub-id-type="pmid">10561351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Louis</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reifenberger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>von Deimling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Figarella-Branger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cavenee</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Ohgaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wiestler</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Kleihues</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ellison</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.</article-title>
            <source>Acta Neuropathol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>131</volume>
            <issue>6</issue>
            <fpage>803</fpage>
            <page-range>803-20</page-range>
            <pub-id pub-id-type="pmid">27157931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Vollmuth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Foltyn-Dumitru</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sahm</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1-Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas.</article-title>
            <source>J Magn Reson Imaging</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>677</fpage>
            <page-range>677-689</page-range>
            <pub-id pub-id-type="pmid">37069792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ostrom</surname>
                <given-names>QT</given-names>
              </name>
              <name>
                <surname>Gittleman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stetson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Virk</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Barnholtz-Sloan</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of gliomas.</article-title>
            <source>Cancer Treat Res</source>
            <year>2015</year>
            <volume>163</volume>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">25468222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kesari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments.</article-title>
            <source>Semin Oncol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>38 Suppl 4</volume>
            <fpage>S2</fpage>
            <page-range>S2-10</page-range>
            <pub-id pub-id-type="pmid">22078644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaichana</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>McGirt</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Niranjan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olivi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Quinones-Hinojosa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature.</article-title>
            <source>Neurol Res</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>931</fpage>
            <page-range>931-9</page-range>
            <pub-id pub-id-type="pmid">19215664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van den Bent</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reijneveld</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Clement</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de Vos</surname>
                <given-names>FYF</given-names>
              </name>
              <name>
                <surname>Wick</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mulholland</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Taphoorn</surname>
                <given-names>MJB</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chinot</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Kros</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>de Heer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Verschuere</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Coens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Golfinopoulos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gorlia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Idbaih</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>1170</fpage>
            <page-range>1170-1179</page-range>
            <pub-id pub-id-type="pmid">30115593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishkanian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laperriere</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Millar</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sahgal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Upfront observation versus radiation for adult pilocytic astrocytoma.</article-title>
            <source>Cancer</source>
            <year>2011</year>
            <month>Sep</month>
            <day>01</day>
            <volume>117</volume>
            <issue>17</issue>
            <fpage>4070</fpage>
            <page-range>4070-9</page-range>
            <pub-id pub-id-type="pmid">21391213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buckner</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Pugh</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Chakravarti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Barger</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Coons</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bullard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Stelzer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brachman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Bahary</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murtha</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Won</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Apr</month>
            <day>07</day>
            <volume>374</volume>
            <issue>14</issue>
            <fpage>1344</fpage>
            <page-range>1344-55</page-range>
            <pub-id pub-id-type="pmid">27050206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kizilbash</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Decker</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Hardie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laack</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Parney</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Uhm</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Buckner</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.</article-title>
            <source>J Neurooncol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-93</page-range>
            <pub-id pub-id-type="pmid">24993250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacroix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abi-Said</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fourney</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Gokaslan</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>DeMonte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>McCutcheon</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Hassenbusch</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sawaya</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.</article-title>
            <source>J Neurosurg</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-8</page-range>
            <pub-id pub-id-type="pmid">11780887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duffau</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A new philosophy in surgery for diffuse low-grade glioma (DLGG): oncological and functional outcomes.</article-title>
            <source>Neurochirurgie</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-8</page-range>
            <pub-id pub-id-type="pmid">23410764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stummer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Coburger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scherer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>von der Brelie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kamp</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>L&#x000f6;hr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamisch</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Skardelly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scholz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schipmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rathert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Pala</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ernemann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stockhammer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goldbrunner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ernestus</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Sabel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tabatabai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bisdas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ganslandt</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Unterberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Tatagiba</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2023</year>
            <month>Dec</month>
            <day>20</day>
            <volume>41</volume>
            <issue>36</issue>
            <fpage>5512</fpage>
            <page-range>5512-5523</page-range>
            <pub-id pub-id-type="pmid">37335962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Farrukh Hameed</surname>
                <given-names>NU</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aibaidula</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of high-field iMRI guided resection in cerebral glioma surgery: A randomized clinical trial.</article-title>
            <source>Eur J Cancer</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>199</volume>
            <fpage>113528</fpage>
            <pub-id pub-id-type="pmid">38218157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotecha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Odia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Khosla</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Key Clinical Principles in the Management of Glioblastoma.</article-title>
            <source>JCO Oncol Pract</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>180</fpage>
            <page-range>180-189</page-range>
            <pub-id pub-id-type="pmid">36638331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaw</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coons</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Brachman</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Buckner</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Stelzer</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Barger</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Sep</month>
            <day>01</day>
            <volume>30</volume>
            <issue>25</issue>
            <fpage>3065</fpage>
            <page-range>3065-70</page-range>
            <pub-id pub-id-type="pmid">22851558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drucker</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Gianinni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Decker</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Diamandis</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Scarisbrick</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>Prognostic significance of multiple kallikreins in high-grade astrocytoma.</article-title>
            <source>BMC Cancer</source>
            <year>2015</year>
            <month>Aug</month>
            <day>01</day>
            <volume>15</volume>
            <fpage>565</fpage>
            <pub-id pub-id-type="pmid">26231762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17930.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schratter-Sehn</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Schipke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Steffal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schratter</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Beneficial outcomes of an interdisciplinary psychoeducative group intervention for patients with malignant gliomas and their relatives].</article-title>
            <source>Wien Med Wochenschr</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>161</volume>
            <issue>1-2</issue>
            <fpage>3</fpage>
            <page-range>3-5</page-range>
            <pub-id pub-id-type="pmid">21312092</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
